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OriginalClinicalScienceçGeneralCenter Volume Is Associated With Outcome
After Pancreas Transplantation Within the
Eurotransplant Region
Wouter Kopp, MD,1,2 Marieke van Meel, BSc,2 Hein Putter, PhD,3 Undine Samuel, MD,2
Helmut Arbogast, MD, PhD,4 Wolfgang Schareck, MD, PhD,5 Jan Ringers, MD,1 and Andries Braat, MD, PhD1Background.Outcome after surgery depends on several factors, among these, the annual volume-outcome relationship. This
might also be the case in a highly complex field as pancreas transplantation. No study has investigated this relationship in a
European setting.Methods.All consecutive pancreas transplantations from January 2008 until December 2013 were included.
Donor-, recipient-, and transplant-related factors were analyzed for their association with patient and graft survivals. Centers were
classified in equally sized groups as being low volume (<5 transplantations on average each year in the 5 preceding years), medium
volume (5-13/year), or high volume (≥13/year).Results. In the study period, 1276 pancreas transplantations were included. Un-
adjusted 1-year patient survival was associated with center volume and was best in high volume centers, compared with medium
and low volume: 96.5%, 94% and 92.3%, respectively (P = 0.017). Pancreas donor risk index (PDRI) was highest in high volume
centers: 1.38 versus 1.21 in medium and 1.25 in low volume centers (P < 0.001). Pancreas graft survival at 1 year did not differ
significantly between volume categories: 86%, 83.2%, and 81.6%, respectively (P = 0.114). Aftermultivariate Cox-regression anal-
ysis, higher PDRI (hazard ratio [HR], 1.60; P < 0.001), retransplantation (HR, 1.91; P = 0.002), and higher recipient body mass in-
dex (HR, 1.04; P = 0.024) were risk factors for pancreas graft failure. High center volume was protective for graft failure (HR, 0.70;
P = 0.037) compared with low center volume.Conclusion.Patient and graft survival after pancreas transplantation are superior
in higher volume centers. High volume centers have good results, even though they transplant organs with the highest PDRI.
(Transplantation 2017;101: 1247–1253)Pancreas transplantation is the only definitive treatmentfor patients with type 1 diabetes mellitus. This can be
as a simultaneous pancreas kidney transplantation (SPK)
in case of end-stage renal disease (ESRD) or as a solitary pan-
creas transplant (pancreas after kidney [PAK], pancreasReceived 6 January 2016. Revision received 19 April 2016.
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Copyright © 2017 Wolters Kluwer Htransplant alone [PTA]) in case of life-threatening hypoglyce-
mic unawareness.1-3 Even though the number of patients on
the waiting list is relatively stable since 2009, optimal usage
of scarce number of potential pancreas allografts is still
highly important.4 Apart from donor, recipient and trans-
plant factors influencing outcome after transplantation,5,6
center factors may also play a significant role.
The Dutch Institute for Clinical Auditing has been work-
ing on valid outcome measures in 18 domains of healthcare,
most of them in oncological surgery. Eurotransplant is a non-
profit organization that facilitates patient-oriented allocation
and cross-border exchange of deceased donor organs. Active
for transplant centers and their associated tissue typing labo-
ratories and donor hospitals in 8 countries, Eurotransplant en-
sures an optimal use of donor organs. To be able to develop
allocation policies based on state-of-the-art medical knowl-
edge, Eurotransplant collects donor, recipient, and center data,
as well as outcome data after transplantation. Information on
center-related outcome, provided that they represent valid and
useful outcome measures, should be publically available: to
centers, to improve their results; to patients, to make a well-
founded decision on a preferred center; and to politicians, to
design legitimate healthcare policies. This information can be
derived fromorganizations, such as theDutch Institute for Clin-
ical Auditing or Eurotransplant or from single-center reports.
With this information, efforts are being put into concen-
trating “high complex, low volume” care in The Netherlands.7
Especially oncology care is subject of this ongoing change.
Transplantation has been the subject of concentration of carewww.transplantjournal.com 1247
ealth, Inc. All rights reserved.
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tation, with currently only 2 of 8 transplant centers with an
active pancreas transplantation program. The question rises
whether this concentration is justified and if the volume out-
come relationship also exists in the field of pancreas trans-
plantation, as has been stated before.8,9 Recently, a German
study advocated for an extensive analysis of volume-outcome
after transplantation.10 In 2014, within Eurotransplant there
were 37 centers with an active pancreas transplant program,
performing a total of 199 vascularized pancreas transplants,
thus averaging an annual number of pancreas transplanta-
tions of a little over 5 each year.4
The aim of this study is to investigate the effect of center
volume on outcome after pancreas transplantation in the
Eurotransplant region.
Design
All consecutive vascularized pancreas transplantations that
were performed in Eurotransplant centers from January 1,
2008, until December 31, 2013, were analyzed. Donor, pro-
curement, recipient, and transplant data that were derived
from the standard Eurotransplant database are shown in
Table 1. Follow-up data were collected through the Euro-
transplant registry. The Eurotransplant registry data were
extracted at October 6, 2015. Graft survival was death cen-
sored. A frequently used definition of graft failure is that graft
failure has occurred, when the recipient had returned to ex-
ogenous insulin therapy. This was the definition that the au-
thors applied to all patients that were transplanted at the
Leiden University Medical Center. For all other centers, it
was unknown which definition was used, so the definition
of pancreas graft failure was left up to the discretion of the
transplant centers. When graft failure and death occurred
at the same day or a graft had not been reported as failed be-
fore recipient death, this was not considered graft failure, and
these cases were censored. The procurement surgeon deter-
mined organ quality (good, acceptable, poor) based on mac-
roscopic evaluation; however, exact criteria were unknown.
Center volume for each year was defined as the total trans-
plant volume of the 5 preceding years, based on standard
Eurotransplant data reports (ie, factor center volume for
2008 was based on average volume from 2003 to 2007, for
2009 based on 2004 to 2008, and so on).11 Volume calcula-
tions were not performed for center before their entry in the
Eurotransplant collaboration. Croatia entered Eurotransplant
in 2007, therefore, only transplants in 2013 (volume based on
2008-2012) were included in the center volume-survival anal-
ysis. Hungary entered in 2013, sowas excluded from the cen-
ter volume-survival analysis. Three equally sized groups were
determined (low, medium, and high volume), based on the
total volume in the 5 preceding years.Multiorgan transplants
were only used to compute the total volume and were ex-
cluded from further analysis. Data in all 3 categories were
pooled in order not to compromise recipient privacy and in
order to not be able to identify individual centers.
Statistical Analysis
Differences between different volume categories were
displayed using pooled sample mean and SE. P values were
calculated using 1-way analysis of variance. Missing values
were imputed using 20 imputation rounds. Missing survival
data were not imputed. Survival analysis for categoricalCopyright © 2017 Wolters Kluwervariables was done using Kaplan-Meier estimates and groups
were compared using Log-rank tests. Continuous variables
were analyzed using Cox proportional hazard models after
testing of the proportional hazards assumption.12 P values
less than 0.05were considered statistically significant. All sig-
nificant factors from univariate survival analysis, as well as
factors that were different among volume groups were en-
tered in multivariate Cox proportional hazards model. To ac-
count for clustering of the data, robust sandwich estimates of
the standard errors were used in multivariate analysis.13 Only
complete cases after multiple imputations were analyzed.
Missing Data Imputation
Recipient weight (6.2%), recipient height (6.2%), and
pancreas cold ischemia (25.4%) had missing values. Vari-
ables thatwere included in the imputationmodel were: donor
age, sex, weight, height, body mass index (BMI), cause of
death, creatinine, DBD versus DCD, pancreas donor risk in-
dex (PDRI), and donor country; recipient age, sex, weight,
height, dialysis type, waiting time; pancreas cold ischemia
time in minutes and hours, total pancreas cold ischemia time
(hours), transplant type (SPK, PAK, PTA), center volume, warm
ischemic period, transplant center, transplant year, organ
quality, perfusion solution. Warm ischemic time, PDRI, cre-
atinine, amylase, lipase, sodium, transplant center, donor
country, perfusion solution, and organ quality were used as
indicators only. Imputation method was automatically se-
lected by SPSS (SPSS version 22, IBM, North Castle, NY)
based on patterns of missing value analysis. To reduce sam-
pling variability from the imputations, 20 imputation rounds
were performed.14 Results of multiple imputations are
shown in Table 2. Recipient BMI and PDRI were calculated
based on the imputed values.RESULTS
In the study period (January 2008 to December 2013),
1276 pancreas transplantations were included in the study.
There were 1148 (90%) SPK transplantations, 84 (6.6%)
PAK transplantation, and 44 (3.4%) PTA transplantations.
During the study and follow-up period, 122 (9.6%) patients
were reported deceased and 256 (20.1%) grafts were re-
ported as failed (death-censored). Mean duration of follow-
up was 3.2 years. Mean pancreas donor risk index was
1.27. Demographics are shown in Table 1.
Patient and Pancreas Graft Survival
Overall patient survival at 180 days, 1 year, and 3 years
was 95.4%, 94.1%, and 91.2%, respectively. Patient death
was associated with higher recipient age (hazard ratio
[HR], 1.03; P = 0.006).
Pancreas graft survival (death-censored) at 180 days,
1 year, and 3 years was 85.3%, 83.7%, and 78.8%, respec-
tively. Pancreas graft failure was associated with higher do-
nor age (P = 0.006), higher donor BMI (P = 0.036), higher
PDRI (P = 0.007), and high recipient BMI (P = 0.027),
retransplantation (P < 0.001) and the use of histidine trypto-
phan ketoglutarate (HTK) as perfusion solution (P = 0.036).
Simultaneous pancreas kidney transplantation (P < 0.001)
was protective in univariate analysis. Results of univariate
analysis on factors associated with pancreas graft failure
are shown in Table 1. Year of transplant was not associated
with pancreas graft survival (P = 0.69). Health, Inc. All rights reserved.
TABLE 1.
Demographics, univariate analysis of association with pancreas graft survivala
n % P χ2
Donors 1276 100
Sexb (male) 0.150 2.070
Male 678 53.1
Female 598 46.9
Cause of deathb 0.076 8.460
Cerebrovascular accident 624 48.9
Trauma 497 38.9
Circulational/anoxia 115 9
CNS tumor 7 0.5
Other 33 2.6
Donor typeb 0.387 0.749
DBD 1268 99.4
DCD 8 0.6
Mean (SD) P HR
Age, yb 32 (12) 0.006 1.014
Weight, kg 71 (14) 0.218 1.006
Height, cmb 173 (12) 0.884 1.001
BMI, kg/m2b 23 (3) 0.036 1.045
Sodium, mmol/L 147 (9) 0.611 1.004
Creatinine, mg/dLb 0.87 (0.58) 0.358 1.089
Amylase, U/L 125 (281) 0.114 1.000
PDRI 1.27c 0.006 1.466
n % P χ2
Transplant









Retransplantation (Y) 118 9.2 <0.001 13.036








Pancreas cold ischemia, hb 10.4c 0.610 1.012






No end-stage renal disease (PAK/PTA) 128 10.0
End-stage renal disease (SPK) 0.140 0.140
Preemptive 218 19.0
Hemodialysis 736 64.1
Peritoneal dialysis 194 16.9
Continued next page
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TABLE 1. (Continued)
Mean (SD) P HR
Age, y 44 (9) 0.487 0.995
BMI, kg/m2 24c 0.025 1.038
Waiting time, y 1.15 (1.3) 0.970 0.998
a Kaplan-Meier estimates (Log rank Mantel-Cox) for categorical variables. Cox proportional hazards for continuous variables.
b PDRI factor.
c Based on imputed data.
d Favorable factor.
1250 Transplantation ■ June 2017 ■ Volume 101 ■ Number 6 www.transplantjournal.comIn a separate subgroup analysis of recipients with ESRD
(SPK recipients), the influence of dialysis modality (either pre-
emptive transplantation, peritoneal dialysis or hemodialysis)
was analyzed for the association with patient and graft sur-
vival. In this analysis, patient (P = 0.235) and graft survivals
(P = 0.140) were not associated with dialysis technique.
Analysis of Center Volume on Outcome
For 1214 (95.1%) transplantations, center volume was
calculated. Nine transplantations (0.7%) were from Hungary
and 53 (4.2%) from Croatia, and these were excluded, because
they had too few preceding years in Eurotransplant. Low vol-
ume centers (<25 transplantation/5 preceding years) performed
396 (32.6%) transplantations, 425 (35%) were performed in
medium volume (25-64 transplantation/5 years) centers and
393 (32.4%) in high volume (≥65 transplantation/5 years) cen-
ters. An overview of number of transplantations in each year by
center category is shown in Table S1 (SDC, http://links.lww.
com/TP/B303). Center demographics are shown in Table 3.
The pooled sample mean PDRI of donors transplanted in dif-
ferent categories differed significantly: 1.25 in low volume
centers, 1.21 in medium volume centers, and 1.38 in high
volume centers (P < 0.001). Post hoc testing (Bonferroni cor-
rections) showed that PDRI only differed between high versus
low (P < 0.001) and high versus medium (P < 0.001), not low
versus medium (P = 0.316). High volume centers transplanted
patients with ESRD more frequently in a preemptive setting,
compared with low and medium volume (P < 0.001). Mean
time from waiting list registration to transplantation was not
significantly different in 3 volume categories (Table 3). The pro-
portional hazards assumption was not violated (P = 0.350).
Patients transplanted in high volume centers had longest
patient survival (P = 0.017) (Figure 1A). Other than age
and center volume, no factors were significantly associated
with patient survival in univariate analysis. After correcting
for recipient age (HR, 1.04; 95% confidence interval [95%
CI], 1.02-1.06; P = 0.001) in a multivariate Cox regression
analysis, high volume (HR, 0.51; 95% CI, 0.32-0.81,TABLE 2.
Imputation of missing data
Original data
n % missing Mean
Recipient height, cm 1198 6.2 172
Recipient weight, kg 1198 6.2 72
Pancreas CIT, h 952 25.4 10.4
a 20 rounds of multiple imputations.
Copyright © 2017 Wolters KluwerP = 0.004) but not medium volume (HR, 0.65; 95% CI,
0.42-1.00; P = 0.052) was protective compared with low vol-
ume. One hundred twelve cases (8.8%) were excluded due
to missing follow-up data or because they were performed
in the first years of Croatian or Hungarian membership
of Eurotransplant.
In univariate analysis, graft survival was not significantly
different among the 3 categories (P = 0.11) (Figure 1B).
Higher PDRI (HR, 1.60; P < 0.001), retransplantation
(HR, 1.91; P = 0.002), and higher recipient BMI (HR, 1.04;
P = 0.024) were independent risk factors for pancreas graft
failure after multivariate Cox regression analysis. Perfusion
with University of Wisconsin (UW) solution was not protective
after multivariate analysis, compared with HTK (P = 0.111) or
other solutions (P = 0.739). Higher center volume was associ-
ated with a lower risk of pancreas graft failure. This effect was
statistically significant for low versus high volume (HR, 0.70;
P = 0.037), but not for low versus medium volume (HR, 0.89;
P = 0.562). Results of multivariate analyses are shown in
Table 4a. One hundred thirty (10.2%) cases were excluded
frommultivariate analysis due to missing follow-up data or be-
cause theywere performed in the first years ofCroatian orHun-
garian membership of Eurotransplant.
In a separate subgroup analysis (Table 4b) with only SPK
transplant included, PDRI, volume category, and perfusion
solution (significant factors from univariate analysis), recipi-
ent BMI, and dialysis category were included in multivariate
analysis. In this multivariate analysis, high PDRI was associ-
ated with graft failure (HR, 1.94; P < 0.001). High volume,
as compared to low volume, was protective for graft failure
(HR, 0.69; P = 0.032), whereas medium volume was not
(HR, 0.91; P = 0.696). The use of HTK was associated with
a higher risk of graft failure compared with UW (HR, 1.56,
P = 0.021). Whether a recipient was transplanted preemp-
tively or while on dialysis was not associated with pancreas
graft survival. Of all 1148 SPK transplantations, 119
(10.4%) were excluded from multivariate analysis due to
missing follow-up data or because they were performed inImputed dataa
(SEM) n % Missing Mean (SEM)
(0.26) 1276 0 172 (0.26)
(0.39) 1276 0 72 (0.40)
(0.09) 1276 0 10.4 (0.08)
 Health, Inc. All rights reserved.
TABLE 3.
Demographics in center categories
Low volume Medium volume High volume Pa
n 396 (32.6%) 425 (35%) 393 (32.4%)
PDRI 1.25 (0.41) 1.21 (0.41) 1.38 (0.46) <0.001
PDRI factors
Donor age, y 33 (11) 30 (12) 35 (13) <0.001
Donor BMI, kg/m2 23.6 (2.8) 22.9 (3.2) 23.3 (2.9) 0.005
Pancreas CIT, h 9.7 (2.6) 10.4 (3.1) 11.2 (2.6) <0.001
SPK transplantation 361 (91.2%) 375 (88.2%) 353 (89.8%) 0.019
Cause of death (stroke) 196 (49.5%) 194 (45.6%) 210 (53.4%) 0.252
DCD 0 (0%) 0 (0%) 8 (2%) <0.001
Recipient age, y 44 (8.7) 44 (8.6) 44 (8.7) 0.660
Recipient BMI, kg/m2 24.2 (4.2) 24.1 (3.8) 24.2 (3.8) 0.593
Sensitized 0.177
6-80% PRA 15 (4%) 28 (6.9%) 21 (5.5%)
>80% PRA 3 (0.8%) 0 (0%) 3 (0.8%)
Waiting time, d 586 (434) 649 (497) 583 (532) 0.087
Retransplantations 32 (8.1%) 46 (10.8%) 40 (10.2%) 0.387
End-stage renal disease (SPK) <0.001
Preemptive 61 (16.9%) 54 (14.4%) 101 (28.6%)
Hemodialysis 243 (67.3%) 262 (69.9%) 192 (54.4%)
Peritoneal dialysis 57 (15.8%) 59 (15.7%) 60 (17.0%)
a One-way ANOVA for continuous variables (mean, SD), χ2 for categorical variables (n, %).
b Low volume (<5 transplantations/year), medium volume (5-13/year) or high volume (≥13/year).
FIGURE 1. A, Kaplan-Meier estimates for patient survival in different volume categories (P = 0.017). B, Kaplan-Meier estimates for pancreas
graft survival in different volume categories (P = 0.114).
© 2016 Wolters Kluwer Kopp et al 1251
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TABLE 4a.
Multivariate analysis of association of risk factors with
pancreas graft survival (all transplantations)
HR (95% CI) P
PDRI 1.60 (1.23-2.07) <0.001
Perfusion solution
UW reference
HTK 1.28 (0.95-1.72) 0.111
Other 0.71 (0.09-5.40) 0.739
Retransplantation 1.91 (1.26-2.91) 0.002
Recipient BMI 1.04 (1.00-1.07) 0.024
Center volume
Low volume reference
Medium volume 0.89 (0.59-1.33) 0.562
High volume 0.70 (0.50-0.98) 0.037
1252 Transplantation ■ June 2017 ■ Volume 101 ■ Number 6 www.transplantjournal.comthe first years of Croatian or Hungarian membership
of Eurotransplant.TABLE 4b.
Multivariate analysis of association of risk factors with
pancreas graft survival (SPK transplantations)
HR (95% CI) P
PDRI 1.94 (1.45-2.60) <0.001
Perfusion solution
UW Reference
HTK 1.56 (1.07-2.28) 0.021
Other 1.02 (0.13-7.93) 0.984
Retransplantation 1.33 (0.84-2.13) 0.227
End-stage renal disease
Preemptive Reference
Hemodialysis 0.97 (0.67-1.39) 0.85
Peritoneal dialysis 1.47 (0.96-2.24) 0.07
Recipient BMI 1.04 (1.00-1.07) 0.047
Center volume
Low volume Reference
Medium volume 0.91 (0.58-1.44) 0.696
High volume 0.69 (0.49-0.97) 0.032DISCUSSION
This study investigates the association of center volume
with outcome after pancreas transplantation. We have
shown that there is a significant relationship between center
volume (defined as volume in 5 preceding years) and out-
come, measured both in patient survival years as in pancreas
graft survival years.
In this study, center volumewas calculated based on the to-
tal number of pancreas transplantations in the previous
5 years. The authors have the opinion that 5 years is a reason-
able timeframe to maintain an experienced program for pan-
creas transplantations. The calculations of volume were
deliberately performed on data from preceding years, in or-
der not to violate assumptions in analysis of longitudinal
data.11 This allowed us to analyze the influence of volume
on outcome, and we excluded the possibility that lower or
higher volume was influenced by previous results. This is
the preferred method to investigate volume-outcome in any
specialty; however, results might have been clouded by the
fact that centers were allowed to migrate between the catego-
ries. It could thus have been that a center was defined as me-
dium volume in the first year, but was analyzed as being low
volume in the following year. This might be considered as a
limitation, but the authors consider this as a strength of the
study, because this method allowed us to establish the exis-
tence of the volume-outcome relationship, without consider-
ing the individual center effect. We acknowledge the fact that
center volume is a surrogate marker, because true quality de-
pends on multiple factors, such as surgical experience, ade-
quate recipient selection and screening, postoperative care,
and long-term follow -up protocols.
Patient survival after transplantation was associated with
recipient age, as well as center volume. Higher recipient age
was a risk factor for patient death, whereas high center vol-
umewas a protective factor. The better patient survival might
be explained by a more rigorous pretransplant screening, es-
pecially regarding cardiovascular status of the intended recip-
ients, and more optimal posttransplant management of
cardiovascular complications in higher volume centers. A re-
cent study from Scalea et al15 demonstrated comparableCopyright © 2017 Wolters Kluwerpatient survival in older recipients in a high volume center
with very strict pretransplant cardiovascular workup.
In univariate analysis, we could not find a significant dif-
ference in graft survival and center volume. However, when
correcting for relevant donor and recipient characteristics in
multivariate analysis, the association with graft failure and
center volume became clear. High volume centers have better
results compared with low volume centers, even though they
are more aggressive in their acceptance policy, indicated by
higher PDRI. Furthermore, from our available recipient data,
we did not establish a significant difference in transplant recip-
ient demographics (age, BMI, waiting time, retransplantation)
that could have explained these results.
Even though it is not the aim of our study, next to the
volume-outcome relationship, several other factors that were
significantly associated with pancreas graft survival were
identified. The first is the pancreas donor risk index (PDRI),
which was found to be associated with graft failure. This is
in line with results from previous studies.16,17 Next to donor
risk, 2 recipient factors were also found to be risk factors for
inferior graft survival. Higher recipient BMI is considered a
risk factor in many types of surgery, being associated with
higher complication rate, and this relationship has recently
been confirmed in 2 studies on pancreas transplantation.18,19
The results of our study confirm this increased risk for recip-
ients with higher BMI. Also, retransplantation was a risk fac-
tor for graft failure (in fact, the strongest). The authors
believe that this is independent of the transplant type, because
we corrected for transplant type using the PDRI. Our results
are in line with previously published results from a large reg-
istry analysis from the United States.20 For the subgroup of
SPK transplantations, retransplantation was not a significant
risk factor. This may be because of small numbers, because
most retransplantations are performed in a PAK/PTA setting.
The protective effect of UW as perfusion solution in uni-
variate analysis disappeared after multivariate analysis of
all transplantations. Possible explanations could be that
HTK was used in higher risk donors, retransplantations or
that HTK was used more frequently in low volume centers.
On the other hand, HTK was identified as an independent Health, Inc. All rights reserved.
© 2016 Wolters Kluwer Kopp et al 1253risk factor for graft failure in the subgroup analysis of SPK
transplantations. The authors think that this study provides
more evidence regarding the optimal cold storage solution
for pancreata.21 To identify an association was not within
the scope of this study and to adequately investigate the rela-
tionship between outcome and perfusion solution a random-
ized controlled trial would be preferred. No association with
transplant year and graft survival was found in this study, in-
dicating that in this cohort, the era effect was of minor impor-
tance. The relatively modern cohort (without major changes
in surgical techniques, preservation methods and immuno-
suppression) may be the reason for this absent association.
This study had some limitations. Most important one is
the definition of graft failure. Because there appears to be
no consensus on the definition of pancreas graft failure,
graft failure was left up to the discretion of the centers.
There may be significant differences in reported survival
rates, depending on the definitions. Furthermore, data on
reported survival and exact numbers lost to follow-up may
not be complete; this may have influenced the results. Also,
Eurotransplant depends on data filled in by the donor and
transplant centers. Some data were missing, however, multi-
ple imputation has been shown to provide valid results and
is an accepted technique to handle missing data.22,23 We be-
lieve that using this technique did not influence the results in
any way and has provided valid estimations of the missing
data. The authors realize that the volume cutoffs that were
chosen are debatable, however, still feasible, when looking
at centers privacy and current group sizes. It could be that,
next to recipient age, patient survival was associated with
factors, such as preexistent peripheral artery disease, coro-
nary or cerebrovascular disease; however, these data were
not available in this study.
In conclusion, it is a remarkable finding that almost one
third of all pancreas transplantations in the Eurotransplant
region are being performed in centers that had performed less
than on average 5 transplantations each year in the 5 preced-
ing years. Given the fact that the highest risk organs are
transplanted in the high volume centers with good outcome,
it is an interesting thought that improving experience in the
pancreas transplant centers may facilitate acceptance and
allow transplantation of higher risk organs and increase
transplant numbers.
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